##### 



Exhibit 10.41
 [..**..] = Certain Confidential Information Contained  in this Document, Marked by Brackets, Has Been  Omitted and Filed Separately with the Securities  and Exchange Commission Pursuant to rule 24b-2  of the Securities Exchange Act of 1934, as Amended.
 Exhibit A-2
 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
(For HDAC Inhibitor Compounds)
 Agreement   Myogen rd NIBRI
  Introduction
    [..**..] Confidential Treatment Requested
 1




---



##### 



ARTICLE I
 Definitions
 1.1. Active Compound
 1.2. Affiliate
 1.3. Cardiac Field
 1.4. Collaboration Agreement
 1.5. Collaboration Compound
 1.6. Collaboration HDAC Inhibitor Compound
 1.7. [Reserved]
 1.8. Commencement Date
 1.9. Compound
 1.10. Controlled
 [..**..] Confidential Treatment Requested
 2




---



##### 



1.11. Co-Promotion Expenses
 (a)
 (b)
 (c)
 (d)
 (e)
 (f)
 (g)
 (h)
 (i)
 (j) provided however
 [..**..] Confidential Treatment Requested
 3




---



##### 



(k)
 (l)
  1.12. Co-Promotion Notice
 1.13. Co-Promotion Response
 1.14. Co-Promotion Share
 1.15. Development Candidate
 1.16. Development Costs provided
 [..**..] Confidential Treatment Requested
 4




---



##### 



(a)
 (b)
 (c)
 (d)
 (e)
 (f)
 1.17. Development Program
 [..**..] Confidential Treatment Requested
 5




---



##### 



1.18. Drug Product
 1.19. European Co-Promotion Share [ ..**.. ] [ ..**.. ] [ ..**.. ]
 1.20. European Countries
 1.21. Expiration Date
 1.22. First Amendment Date
 1.23. First Commercial Sale
 1.24. GCP
 [..**..] Confidential Treatment Requested
 6




---



##### 



1.25. GLP
 1.26. GMP
 1.27. Gross Contribution [ ..**.. ]
 (a) [ ..**.. ]
 (b) [ ..**.. ]
 1.28. HDAC
 1.29. HDAC Inhibitor Compound
 1.30. IC 50
 1.31. Improvement
 1.32. Improvement Patent
 [..**..] Confidential Treatment Requested
 7




---



##### 



1.33. IND
 1.34.  In Vivo Validation in vivo in vivo
 1.35. Joint Know-How
 1.36. Joint Patent
 1.37. Joint Technology
 1.38. Know-How
 1.39. Know-How Period
 [..**..] Confidential Treatment Requested
 8




---



##### 



1.40. Licensed Field
 1.41. Licensed Patents
 1.42. Listed Country
 1.43. Live Claim .
 1.44. Myogen Compound
 1.45. Myogen Know-How
 1.46. Myogen Patents
 1.47. Myogen Target
 1.48. Myogen Technology
 1.49. NDA
 [..**..] Confidential Treatment Requested
 9




---



##### 



1.50. Net Sales
 (a)
 (b)
 (c)
 (d)
 (e)
 (f)
 (g)
 (h)
 (i) [ ..**.. ]
 (j)
 provided that
 [..**..] Confidential Treatment Requested
 10




---



##### 



(i)
 (ii)
 (iii)
 1.51. NIBRI Compound
 1.52. NIBRI Know-How
 1.53. NIBRI Patents
 [..**..] Confidential Treatment Requested
 11




---



##### 



1.54. NIBRI Technology
 1.55. NIBRI HDAC Inhibitor Compound
 (a) 50 m in vitro
 (b) 50 m in vitro
 (c) 50 in vitro
 (d)
 [..**..] Confidential Treatment Requested
 12




---



##### 



In-Licensed NIBRI HDAC
Inhibitor Compounds
 1.56. Patent Period
 1.57. Patents
 1.58. Person
 1.59. Phase I Clinical Trial
 1.60. Phase II Clinical Trial
 1.61. Phase III Clinical Trial
 1.62. Phase IV Clinical Trial
 [..**..] Confidential Treatment Requested
 13




---



##### 



1.63. Registration Filing
 1.64. Regulatory Approval
 1.65. Regulatory Expenses
 1.66. Technology
 1.67. Territory [ ..**.. ]
 1.68. Third Party
 ARTICLE II
 Rights and Licenses
 2.1. NIBRI Rights
 [..**..] Confidential Treatment Requested
 14




---



##### 



2.2. Scope of Exclusivity; Diligence; Development Responsibility.
 (a)
 (i)
 (ii)
 (b)
 [..**..] Confidential Treatment Requested
 15




---



##### 



(c)
 2.3. Joint Inventions and Joint Patents. Joint Inventions
 2.4. Inventions Necessary to the License.
 2.5. Diagnostic and Prognostic Products.
 [..**..] Confidential Treatment Requested
 16




---



##### 



ARTICLE III
 Development and Commercialization
 3.1. Development and Commercialization Rights. .
 3.2. Information Transfer.
 [..**..] Confidential Treatment Requested
 17




---



##### 



3.3. Regulatory Approvals.
 3.4. Due Diligence.
 3.5. Co-Funding and Co-Promotion Option.
 (a) Co-Promotion Notice [ ..**.. ] Co-Promotion Response
 [..**..] Confidential Treatment Requested
 18




---



##### 



Co-Promotion Share provided [ ..**.. ] [ ..**.. ]
 (b) provided however
 (c) Definitive
Agreement
 [..**..] Confidential Treatment Requested
 19




---



##### 



(i)
 (ii)
 (iii) [ ..**.. ] [ ..**.. ]
 (iv) Expense Reimbursement [ ..**.. ] [ ..**.. ]
 [..**..] Confidential Treatment Requested
 20




---



##### 



[ ..**.. ]
 (v)
 (vi)
 (d)
 (e) [ ..**.. ]
 3.6. NIBRI HDAC Inhibitor Compounds.
 (a)
 [..**..] Confidential Treatment Requested
 21




---



##### 



then
 (b) [ ..**.. ] [ ..**.. ]
 ARTICLE IV
 Milestone and Royalty Payments
 4.1. Milestone Payments.
 (a)
 [..**..] Confidential Treatment Requested
 22




---



##### 



(b) [ ..**.. ]
 [..**..] Confidential Treatment Requested
 23




---



##### 



FuturePrior Clinical
    
    NIBRI
    
    CollaborationNIBRI HDAC
    
    HDAC
    
    HDACDEVELOPMENTAL
    
    Inhibitor
    
    Inhibitor
    
    InhibitorMILESTONE:
    
    Compounds
    
    Compounds
    
    CompoundsPre-Clinical Milestones:
    
    Validation of high-throughput
assays*
    
    [..**..]
    
    [..**..]
    
    [..**..]
    
    In vitrovalidation of lead
compound*
    
    [..**..]
    
    [..**..]
    
    [..**..]
    
    In VivoValidation of lead
compound or use of the lead compound as a
starting point for medicinal chemistry
and/or SAR exploration*
    
    [..**..]
    
    [..**..]
    
    [..**..]
    
    Additional payment at the earlier
of In VivoValidation or second
(2nd) anniversary of the First
Amendment Date**
    
    [..**..]
    
    [..**..]
    
    [..**..]
    
    Completion of Tox/ADME screening
and preclinical candidate determination*
    
    [..**..]
    
    [..**..]
    
    [..**..]Clinical Milestones:
    
    IND filing
    
    [..**..]
    
    [..**..]
    
    [..**..]
    
    Initiation of Phase II clinical
evaluation
    
    [..**..]
    
    [..**..]
    
    [..**..]
    
    Initiation of Phase III clinical
studies
    
    [..**..]
    
    [..**..]
    
    [..**..]
    
    Regulatory filing in the U.S.
    
    [..**..]
    
    [..**..]
    
    [..**..]
    
    First regulatory filing in the
E.U.
    
    [..**..]
    
    [..**..]
    
    [..**..]
    
    Regulatory Approval in the U.S.
    
    [..**..]
    
    [..**..]
    
    [..**..]
    
    First Regulatory Approval in the
E.U.
    
    [..**..]
    
    [..**..]
    
    [..**..]
 
 *   Criteria for determining the achievement of any Milestone will be established by the JSC.** For the avoidance of doubt, this milestone is payable only once. (c) Prior Clinical NIBRI HDAC Inhibitor
Compound Future NIBRI HDAC Inhibitor Compound
 [..**..] Confidential Treatment Requested
 24




---



##### 



(d) Increased
Milestone Payments [..**..]
  4.2. Royalty Payments During the Patent Period.
 (a) Collaboration HDAC Inhibitor Compounds [..**..] [..**..]
 [..**..] Confidential Treatment Requested
 25




---



##### 



[..**..]
 (b) NIBRI HDAC Inhibitor Compounds [..**..] [..**..]
 4.3. Royalty Payments During a Know-How Period [..**..] provided however
 4.4. Responsibility for Myogens Third Party Royalty Obligations.
 [..**..] Confidential Treatment Requested
 26




---



##### 



4.5. Reduced Royalty Obligations.
 (a) [..**..] provided that
 (b) [..**..]
 (c) [..**..] provided however [..**..]
 4.6. Certain Understandings Regarding Royalty Payments.
 [..**..] Confidential Treatment Requested
 27




---



##### 



ARTICLE V
 Reporting Obligations
 5.1. Development Reports.
 5.2. Sales Reports and Records.
 [..**..] Confidential Treatment Requested
 28




---



##### 



ARTICLE VI
 Confidentiality
 6.1. Undertaking. Receiving
Party Proprietary Party
 (a)
 (b)
 (c)
 [..**..] Confidential Treatment Requested
 29




---



##### 



6.2. Exceptions.
 (a)
 (b)
 (c)
 6.3.
 (a)
 (b)
 6.4. Publicity.
 6.5. Survival.
 [..**..] Confidential Treatment Requested
 30




---



##### 



ARTICLE VII
 Patents
 7.1. Preparation.
 7.2. Infringement.
 [..**..] Confidential Treatment Requested
 31




---



##### 



ARTICLE VIII
 Term and Termination
 8.1. Term. Patent Period Know-How Period Expiration Date
 8.2. Material Breach by NIBRI.
 [..**..] Confidential Treatment Requested
 32




---



##### 



8.3. Termination.
 8.4. Effect of Termination.
 [..**..] Confidential Treatment Requested
 33




---



##### 



ARTICLE IX
 Miscellaneous Provisions
 9.1. Governing Law, and Jurisdiction.
 9.2. No Warranty.
 9.3. Third Party Actions.
 (a)
 [..**..] Confidential Treatment Requested
 34




---



##### 



(b) provided that
 [..**..] Confidential Treatment Requested
 35




---



##### 



9.4. Force Majeure.
 9.5. Waiver.
 9.6. Severability.
 9.7. Government Acts.
 9.8. Government Approvals.
 [..**..] Confidential Treatment Requested
 36




---



##### 



9.9. Export Controls.
 9.10. Assignment. without except provided that [..**..]
 [..**..] Confidential Treatment Requested
 37




---



##### 



9.11. Counterparts.
 9.12. No Agency.
 9.13. Notice.
  
  rd
 [..**..] Confidential Treatment Requested
 38




---



##### 



rd
 9.14. Headings.
 9.15. Authority.
 9.16. Entire Agreement.
 [..**..] Confidential Treatment Requested
 39




---



##### 



MYOGEN, INC.By:Title:Date of Signature:NOVARTIS INSTITUTES FOR BIOMEDICALRESEARCH, INC.By:Title:Date of Signature:
 [..**..] Confidential Treatment Requested
 40




---



##### 



Schedule 1.42
 Listed Countries




---



##### 



Schedule 1.46
 Myogen Patents
 Schedule 1.46 Myogen PatentsPATENTS
    
    Filing Date
    
    App. No.
    
    Country
    
    Pat. No.
    
    Issue Date
    
    Subject MatterMYOG:004-USD1
    
    4/25/2000
    
    09/558,472
    
    U.S.
    
    
    
    
    
    Alpha Myosin Heavy Chain Gene TherapyMYOG:004-USD2
    
    10/1/2001
    
    09/969,086
    
    U.S.
    
    7,049,066
    
    5/23/2006
    
    Alpha Myosin Heavy Chain Therapeutic/ScreeningMYOG:004-USD3
    
    2/25/2005
    
    11/067,502
    
    U.S.
    
    
    
    
    
    Alpha Myosin Heavy Chain TreatmentMYOG:004-WO
    
    1/30/1998
    
    PCT/US98/01983
    
    PCT
    
    
    
    
    
    Alpha Myosin Heavy ChainMYOG:004-CA
    
    7/29/1999
    
    2,278,465
    
    Canada
    
    
    
    
    
    Alpha Myosin Heavy ChainMYOG:004-EP
    
    7/30/1999
    
    98906089.2
    
    Europe
    
    
    
    
    
    Alpha Myosin Heavy ChainMYOG:004-JP
    
    7/30/1999
    
    10-533182
    
    Japan
    
    
    
    
    
    Alpha Myosin Heavy ChainMYOG:005-US
    
    4/1/1998
    
    09/053,293
    
    U.S.
    
    6,218,597
    
    4/17/2001
    
    Transgenic mice w/cardiac specific promotersMYOG:006-US
    
    9/26/1997
    
    08/938,105
    
    U.S.
    
    6,353,151
    
    3/5/2002
    
    Transgeneic alpha myosinMYOG:006-EP
    
    5/24/1999
    
    97943597.1
    
    Europe
    
    
    
    
    
    Alpha Myosin TransgenesMYOG:007-US
    
    5/26/1998
    
    09/047,755
    
    U.S.
    
    6,203,776
    
    3/20/2001
    
    Methods for identifying adrenergic receptorsMYOG:013-US
    
    6/19/1998
    
    09/100,497
    
    U.S.
    
    5,998,458
    
    12/7/1999
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:013-WO
    
    6/24/1998
    
    PCT/US98/13442
    
    PCT
    
    
    
    
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:013-AU
    
    1/6/2000
    
    81740/98
    
    Australia
    
    731,656
    
    7/19/2001
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:013-CA
    
    12/23/1999
    
    2,295,094
    
    Canada
    
    
    
    
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:013-EP
    
    1/25/2000
    
    198,931,687
    
    Europe
    
    
    
    
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:013-JP
    
    12/27/1999
    
    11-505056
    
    Japan
    
    
    
    
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:020-US
    
    10/15/1998
    
    09/173,798
    
    U.S.
    
    6,201,165
    
    3/13/2001
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-WO
    
    10/16/1998
    
    PCT/US98/21988
    
    PCT
    
    
    
    
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-AU
    
    4/16/2000
    
    10992/99
    
    Australia
    
    755428
    
    8/16/2002
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-CA
    
    4/16/2000
    
    2,315,244
    
    Canada
    
    
    
    
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-EP
    
    4/16/2000
    
    98953672.7
    
    Europe
    
    
    
    
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-JP
    
    4/16/2000
    
    2000-516026
    
    Japan
    
    
    
    
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-MX
    
    4/14/2000
    
    0003678
    
    Mexico
    
    
    
    
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:023-US
    
    10/15/1998
    
    09/173,795
    
    U.S.
    
    6,673,768
    
    1/6/2004
    
    Calcineurin TherapiesMYOG:024-US
    
    11/10/1999
    
    09/438,075
    
    U.S.
    
    6,372,957
    
    4/16/2002
    
    MEF2 methods of treatmentMYOG:024-USC1
    
    1/9/2002
    
    10/043,658
    
    U.S.
    
    
    
    
    
    MEF2 screening methodsMYOG:024-WO
    
    11/10/1999
    
    PCT/US99/26725
    
    PCT
    
    
    
    
    
    MEF2MYOG:024-CA
    
    5/7/2001
    
    2,350,086
    
    Canada
    
    
    
    
    
    MEF2MYOG:024-EP
    
    5/21/2001
    
    99971848.9
    
    Europe
    
    
    
    
    
    MEF2MYOG:024-JP
    
    5/10/2001
    
    2000-581187
    
    Japan
    
    
    
    
    
    MEF2MYOG:025-US
    
    10/15/1998
    
    09/173,799
    
    U.S.
    
    6,657,104
    
    12/2/2003
    
    Calcineurin transgenicsMYOG:026-US
    
    8/20/2000
    
    09/643,206
    
    U.S.
    
    6,632,628
    
    8/20/2000
    
    HDAC screening and treatmentMYOG:026-USD1
    
    8/20/2003
    
    10/637,403
    
    U.S.
    
    
    
    
    
    HDAC transgenicsMYOG:026-WO
    
    8/20/2000
    
    PCT/US00/22958
    
    PCT
    
    
    
    
    
    Class II HDACsMYOG:026-CA
    
    2/14/2002
    
    2,382,045
    
    Canada
    
    
    
    
    
    Class II HDACsMYOG:026-EP
    
    3/13/2002
    
    00955805.7
    
    Europe
    
    
    
    
    
    Class II HDACsMYOG:026-JP
    
    2/19/2002
    
    2001-518892
    
    Japan
    
    
    
    
    
    Class II HDACsMYOG:028-US
    
    7/18/2001
    
    09/908,988
    
    U.S.
    
    6,740,751
    
    5/25/2004
    
    Muscle Ring Finger Proteins (MURFS) Screening and TreatmentMYOG:028-USD1
    
    2/10/2004
    
    10/775,627
    
    U.S.
    
    7,005,512
    
    2/28/2006
    
    Muscle Ring Finger Proteins (MURFS) Screening and TreatmentMYOG:028-USD2
    
    2/10/2004
    
    10/775,649
    
    U.S.
    
    issue fee
    
    paid
    
    Muscle Ring Finger Proteins (MURFS)MYOG:029-US
    
    4/16/1998
    
    09/061,417
    
    U.S.
    
    
    
    
    
    NF-AT3 inhibitorsMYOG:029-WO
    
    10/16/1998
    
    PCT/US98/21845
    
    PCT
    
    
    
    
    
    NF-AT3 inhibitorsMYOG:029-AU
    
    10/15/1998
    
    98058/98
    
    Australia
    
    748334
    
    9/12/2002
    
    NF-AT3 inhibitorsMYOG:029-CA
    
    4/10/2000
    
    2,306,448
    
    Canada
    
    
    
    
    
    NF-AT3 inhibitorsMYOG:029-EP
    
    5/16/2000
    
    9895233.7
    
    Europe
    
    
    
    
    
    NF-AT3 inhibitorsMYOG:029-JP
    
    4/17/2000
    
    2000-516024
    
    Japan
    
    
    
    
    
    NF-AT3 inhibitorsMYOG:034-US
    
    9/26/2002
    
    10/256,221
    
    U.S.
    
    6,707,686
    
    3/16/2004
    
    HDAC InhibitorsMYOG:034-USC1
    
    3/16/2004
    
    10/801,985
    
    U.S.
    
    6,946,441
    
    9/20/2005
    
    Inhibiting HDACs




---



##### 



Schedule 1.46 Myogen PatentsPATENTS
    
    Filing Date
    
    App. No.
    
    Country
    
    Pat. No.
    
    Issue Date
    
    Subject MatterMYOG:034-USC2
    
    7/26/2005
    
    11/190,074
    
    U.S.
    
    
    
    
    
    Inhibiting HDACsMYOG:034-USC3
    
    8/30/2005
    
    11/215,844
    
    U.S.
    
    
    
    
    
    Inhibiting HDACsMYOG:034-EP
    
    9/27/2001
    
    02/021678.8
    
    Europe
    
    1,297,851
    
    1/26/2005
    
    Inhibiting HDACsMYOG:034-EPD1
    
    1/25/2005
    
    5001443
    
    Europe
    
    
    
    
    
    Inhibiting HDACsMYOG:034-JP
    
    9/27/2001
    
    2002-284313
    
    Japan
    
    
    
    
    
    Inhibiting HDACsMYOG:035-US
    
    1/21/2003
    
    10/348,598
    
    U.S.
    
    
    
    
    
    Hypertrophic Cell LineMYOG:036-US
    
    2/13/2001
    
    09/782,953
    
    U.S.
    
    
    
    
    
    MCIP's screening, treatment, transgenics, antibodiesMYOG:036-WO
    
    2/13/2001
    
    PCT/US01/21662
    
    PCT
    
    
    
    
    
    MCIP's screening, treatment, transgenics, antibodiesMYOG:036-CA
    
    1/24/2003
    
    2,415,967
    
    Canada
    
    
    
    
    
    MCIP's screening, treatment, transgenics, antibodiesMYOG:036-EP
    
    2/5/2003
    
    1952568.2
    
    Europe
    
    
    
    
    
    MCIP's screening, treatment, transgenics, antibodiesMYOG:036-JP
    
    12/26/2002
    
    2002-509354
    
    Japan
    
    
    
    
    
    MCIP's screening, treatment, transgenics, antibodiesMYOG:037-US
    
    8/20/2003
    
    10/644,659
    
    U.S.
    
    
    
    
    
    STARS screening, treatment, transgenics, antibodiesMYOG:044-US
    
    5/21/2003
    
    10/848,820
    
    U.S.
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-WO
    
    5/21/2003
    
    PCT/US04/015715
    
    PCT
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-AU
    
    5/21/2003
    
    2004249114
    
    Australia
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-BR
    
    5/21/2003
    
    
    
    Brazil
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-CA
    
    5/21/2003
    
    
    
    Canada
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-CN
    
    5/21/2003
    
    
    
    China
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-EP
    
    5/21/2003
    
    
    
    Europe
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-IN
    
    5/21/2003
    
    
    
    India
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-JP
    
    5/21/2003
    
    
    
    Japan
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-MX
    
    5/21/2003
    
    
    
    Mexico
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:045-US
    
    11/3/2004
    
    10/980,612
    
    U.S.
    
    
    
    
    
    Alpha myocin modulating compound 'R' enatiomerMYOG:045-WO
    
    11/3/2004
    
    PCT/US04/036569
    
    PCT
    
    
    
    
    
    Alpha myocin modulating compound 'R' enatiomerMYOG:046-US
    
    11/3/2004
    
    10/980,605
    
    U.S.
    
    
    
    
    
    Alpha myocin modulating compound 'S' enatiomerMYOG:046-US
    
    11/3/2004
    
    PCT/US04/036568
    
    PCT
    
    
    
    
    
    Alpha myocin modulating compound 'S' enatiomerMYOG:047-US
    
    11/13/2004
    
    10/988,192
    
    U.S.
    
    
    
    
    
    TRP ChannelMYOG:047-WO
    
    11/13/2004
    
    PCT/US04/037858
    
    PCT
    
    
    
    
    
    TRP ChannelMYOG:048-US
    
    12/23/2004
    
    11/018,426
    
    U.S.
    
    
    
    
    
    5-HT2 receptorsMYOG:048-WO
    
    12/23/2004
    
    PCT/US04/042922
    
    PCT
    
    
    
    
    
    5-HT2 receptorsMYOG:049-US
    
    12/23/2004
    
    11/018,383
    
    U.S.
    
    
    
    
    
    5-HT2 receptor binding compoundsMYOG:049-WO
    
    12/23/2004
    
    PCT/US04/042921
    
    PCT
    
    
    
    
    
    5-HT2 receptor binding compoundsMYOG:050-US
    
    2/2/2005
    
    11/049,630
    
    U.S.
    
    
    
    
    
    PRK (HDAC kinase II)MYOG:050-WO
    
    2/2/2005
    
    PCT/US05/002808
    
    PCT
    
    
    
    
    
    PRK (HDAC kinase II)MYOG:054-US
    
    4/5/2005
    
    11/099,417
    
    U.S.
    
    
    
    
    
    Nuclear exportMYOG:054-WO
    
    4/5/2005
    
    PCT/US05/011264
    
    PCT
    
    
    
    
    
    Nuclear exportMYOG:057-WO
    
    9/19/2005
    
    PCT/US05/033461
    
    PCT
    
    
    
    
    
    P38 MCIPMYOG:058-US
    
    8/15/2005
    
    11/203,828
    
    U.S.
    
    
    
    
    
    KuMYOG:060-USP1
    
    7/13/2005
    
    60/699,189
    
    U.S.
    
    
    
    
    
    Proteasome inhibitorsMYOG:062-USP1
    
    11/18/2005
    
    60/737,952
    
    U.S.
    
    
    
    
    
    CAMKII/Calpain/HDACsUTSD:803-US
    
    5/30/2002
    
    10/159,971
    
    U.S.
    
    6,924,415
    
    8/2/2005
    
    MEK5USTD:803-USD1
    
    4/21/2005
    
    11/089,425
    
    U.S.
    
    
    
    
    
    MEK5UTSD:803-CA
    
    5/29/2002
    
    2,384,907
    
    Canada
    
    
    
    
    
    MEK5UTSD:803-JP
    
    11/22/2001
    
    2001-358595
    
    Japan
    
    
    
    
    
    MEK5USTD:1771-USP1
    
    5/3/2006
    
    not yet assigned
    
    U.S.
    
    
    
    
    
    CAMTA